MedTrace Logo

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07090330 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-03-17

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Conditions

Interventions

DRUG

ORKA-001 Induction Dose

ORKA-001 Induction Dose, administered by subcutaneous (SC) injection

OTHER

Placebo

Placebo administered by subcutaneous (SC) injection

DRUG

ORKA-001 Maintenance Dose

ORKA-001 Maintenance Dose, administered by subcutaneous (SC) injection

Sponsors & Collaborators

  • Oruka Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-18
Primary Completion
2026-04-30
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07090330 on ClinicalTrials.gov